Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18187103 | 0.85 | BDKRB1 (0.33) | KDM4EGAAS1PR3 | |
| SCHEMBL698954 | 0.80 | KDM4E (0.34) | KDM4E | |
| SCHEMBL14723052 | 0.78 | CNR1 (0.33) | KDM4ES1PR3 | |
| SCHEMBL13552249 | 0.76 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL17429459 | 0.76 | HTR2A (0.52) | HTR2AHTR2C | |
| SCHEMBL15155115 | 0.73 | HTR2A (0.32) | HTR2AHTR2C | |
| SCHEMBL3709944 | 0.72 | HTR2A (0.50) | HTR2AHTR2C | |
| SCHEMBL12615726 | 0.70 | HTR2A (0.35) | KDM4EHTR2AHTR2C | |
| SCHEMBL3710160 | 0.70 | — | — | |
| SCHEMBL17275595 | 0.68 | RAPGEF4 (0.45) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108174603-B | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators | 阿芮纳制药有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3292114-B1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-108174603-A | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators for the treatment or prevention of disorders related thereto | 阿芮纳制药有限公司 | 2018-06-15 | — | — | CN | disclosed |
| EP-3292114-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9676758-B2 | 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto | Arena Pharmaceutical, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160318911-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2016176571-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| CN-104024248-A | SERINE/THREONINE PAK1 INHIBITORS | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318911-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | GPR52, HTR2A, HTR2C | KDM4E 4778/4885GAA 1191/4885S1PR3 3037/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | KDM4E 2561/4885GAA 3564/4885S1PR3 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.